IL124073A - Aloe vera pill pills and their preparation - Google Patents

Aloe vera pill pills and their preparation

Info

Publication number
IL124073A
IL124073A IL12407398A IL12407398A IL124073A IL 124073 A IL124073 A IL 124073A IL 12407398 A IL12407398 A IL 12407398A IL 12407398 A IL12407398 A IL 12407398A IL 124073 A IL124073 A IL 124073A
Authority
IL
Israel
Prior art keywords
fluoxetine
enteric
layer
pellet
hpmcas
Prior art date
Application number
IL12407398A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25349313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL124073(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL124073A publication Critical patent/IL124073A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL12407398A 1997-05-29 1998-04-13 Aloe vera pill pills and their preparation IL124073A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/867,196 US5910319A (en) 1997-05-29 1997-05-29 Fluoxetine enteric pellets and methods for their preparation and use

Publications (1)

Publication Number Publication Date
IL124073A true IL124073A (en) 2002-02-10

Family

ID=25349313

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12407398A IL124073A (en) 1997-05-29 1998-04-13 Aloe vera pill pills and their preparation

Country Status (46)

Country Link
US (3) US5910319A (sr)
JP (1) JP3210288B2 (sr)
KR (1) KR100549473B1 (sr)
CN (2) CN1161109C (sr)
AR (1) AR011728A1 (sr)
AT (1) AT408068B (sr)
AU (1) AU726690B2 (sr)
BE (1) BE1011925A3 (sr)
BR (1) BR9801989A (sr)
CA (1) CA2234826C (sr)
CH (1) CH693018A5 (sr)
CO (1) CO4940407A1 (sr)
CZ (1) CZ290582B6 (sr)
DE (1) DE19823940B4 (sr)
DK (1) DK176776B1 (sr)
ES (1) ES2161574B1 (sr)
FI (1) FI119971B (sr)
FR (1) FR2763846B1 (sr)
GB (1) GB2325623B (sr)
GR (1) GR980100188A (sr)
HK (1) HK1034902A1 (sr)
HU (1) HUP9800882A3 (sr)
ID (1) ID20343A (sr)
IL (1) IL124073A (sr)
IT (1) ITMI980908A1 (sr)
LT (1) LT4477B (sr)
LU (1) LU90245B1 (sr)
LV (1) LV12176B (sr)
MY (1) MY118139A (sr)
NL (1) NL1009259C2 (sr)
NO (1) NO317743B1 (sr)
NZ (1) NZ330192A (sr)
PE (1) PE75399A1 (sr)
PL (1) PL192293B1 (sr)
PT (1) PT102152B (sr)
RO (1) RO120043B1 (sr)
RS (1) RS49827B (sr)
RU (1) RU2164405C2 (sr)
SE (1) SE522914C2 (sr)
SG (1) SG72805A1 (sr)
SI (1) SI9800128B (sr)
SV (1) SV1998000052A (sr)
TR (1) TR199800937A2 (sr)
TW (1) TWI239838B (sr)
UA (1) UA48193C2 (sr)
ZA (1) ZA983173B (sr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
ATE367153T1 (de) * 1999-05-20 2007-08-15 Elan Corp Plc Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
AU762934B2 (en) 1999-09-03 2003-07-10 Allergan Sales, Llc Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
CN1094347C (zh) * 1999-11-15 2002-11-20 广东药学院药物研究所 一种治疗前列腺良性增生症的控释微丸及其制备方法
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
JP4181738B2 (ja) * 2000-08-25 2008-11-19 信越化学工業株式会社 腸溶性コーティング製剤の製造方法
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
AU2002212102A1 (en) * 2000-11-08 2002-05-21 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
WO2003013480A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2002361495A1 (en) * 2002-12-24 2004-07-22 Lupin Limited Enteric coated fluoxetine composition
US8614247B2 (en) * 2003-04-10 2013-12-24 Institut National De La Sante Et De La Recherche Medicale Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof
MXPA05012900A (es) 2003-05-30 2006-02-22 Ranbaxy Lab Ltd Derivados de pirrol sustituidos.
US20050176693A1 (en) * 2003-08-12 2005-08-11 Boissonneault Roger M. Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
EP1699458A4 (en) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITION
JP4277904B2 (ja) * 2004-04-30 2009-06-10 アステラス製薬株式会社 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
EP1730132A2 (en) * 2004-12-23 2006-12-13 Teva Pharmaceutical Industries Ltd Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
AU2006274565B2 (en) * 2005-08-02 2012-05-17 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
US20070155820A1 (en) * 2005-11-23 2007-07-05 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
WO2007100822A2 (en) * 2006-02-24 2007-09-07 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium pharmaceutical compositions
CN101057837B (zh) * 2006-04-20 2010-12-22 湖南九典制药有限公司 一种右旋酮洛芬肠溶微丸及制备方法
EP2016066A4 (en) * 2006-05-10 2010-11-24 Reddys Lab Ltd Dr PROCESS FOR PREPARING DULOXETINE
CA2651716A1 (en) * 2006-05-22 2007-12-06 Gershon Kolatkar Duloxetine hydrochloride delayed release formulations
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20090252787A1 (en) * 2006-07-28 2009-10-08 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US20090175935A1 (en) * 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
PT2317852E (pt) 2008-07-16 2015-03-24 Richter Gedeon Nyrt Formulações farmacêuticas contendo ligandos de recetor de dopamina
JPWO2010026993A1 (ja) * 2008-09-03 2012-02-02 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
CN101804145B (zh) * 2009-02-12 2012-11-14 杭州赛利药物研究所有限公司 一种大蒜油肠溶微丸胶囊及其制备方法
US20120207825A1 (en) * 2009-09-17 2012-08-16 Sunilendu Bhushan Roy Pharmaceutical compositions for reducing alcohol-induced dose dumping
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
EP3446713A3 (en) * 2012-05-02 2019-05-15 Capsugel Belgium NV Aqueous dispersions of controlled release polymers and shells and capsules thereof
CN102716084B (zh) * 2012-06-29 2013-09-25 海南美大制药有限公司 盐酸氟西汀脂质体固体制剂
ES2706994T3 (es) 2012-09-03 2019-04-02 Daiichi Sankyo Co Ltd Composición farmacéutica de liberación prolongada de administración oral que contiene clorhidrato de hidromorfona
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3145496B1 (en) 2014-05-20 2020-03-18 Dow Global Technologies LLC Capsule shells comprising an esterified cellulose ether
KR20170005833A (ko) * 2014-05-20 2017-01-16 다우 글로벌 테크놀로지스 엘엘씨 부분적으로 중화된 에스테르화 셀룰로오스 에테르를 포함하는 분산물
WO2015187874A1 (en) * 2014-06-07 2015-12-10 Structure-Ase, Inc. A method for the detection and/or diagnosis of eating disorders and malnutrition using x-ray diffraction
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CA3096453A1 (en) * 2017-04-13 2018-10-18 Chase Therapeutics Corporation Pharmaceutical combination comprising fluoxetine and pramipexole and its use for treating synucleinopathies
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN107898942B (zh) * 2017-11-24 2021-01-26 一力制药(罗定)有限公司 一种感冒清热胶囊及其制备方法
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
JPS517116A (en) 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4444778A (en) * 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4918242A (en) 1988-03-30 1990-04-17 Aldrich Chemical Company, Inc. Novel optically 1,3-phenoxypropylhalides
CA1337955C (en) * 1988-09-26 1996-01-23 Thomas A. Almquist Recoating of stereolithographic layers
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
JPH04202124A (ja) * 1990-11-29 1992-07-22 Fuji Kagaku Kogyo Kk 噴霧乾燥造粒法による薬物放出の制御された製剤の製造法
WO1992013452A1 (en) * 1991-02-04 1992-08-20 Young James W Methods of use and compositions of r(-) fluoxetine
WO1992019241A1 (en) * 1991-05-07 1992-11-12 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
DE69322077T2 (de) * 1992-03-25 1999-04-08 Depomed Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06293633A (ja) * 1993-04-05 1994-10-21 Shin Etsu Chem Co Ltd 水性腸溶性エマルジョンの製造方法
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
EP0726761B1 (en) * 1993-11-03 2001-01-10 ISOMED, Inc. Microparticular pharmaceutical compositions in micellar form
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
JPH08109126A (ja) * 1994-10-07 1996-04-30 Amano Pharmaceut Co Ltd 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
JPH08245423A (ja) * 1995-03-06 1996-09-24 Shionogi & Co Ltd 水系腸溶性コーティング液
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
TR199800937A3 (tr) 1999-10-21
HK1034902A1 (en) 2001-11-09
DK176776B1 (da) 2009-08-10
NO982197L (no) 1998-11-30
GB2325623B (en) 1999-04-14
AR011728A1 (es) 2000-08-30
ES2161574B1 (es) 2002-06-16
TWI239838B (en) 2005-09-21
TR199800937A2 (xx) 1999-10-21
SV1998000052A (es) 1999-03-16
PT102152B (pt) 2000-09-29
SG72805A1 (en) 2000-05-23
GR980100188A (el) 1999-01-29
GB2325623A (en) 1998-12-02
US5910319A (en) 1999-06-08
RU2164405C2 (ru) 2001-03-27
CN1212834C (zh) 2005-08-03
BE1011925A3 (fr) 2000-03-07
CN1200924A (zh) 1998-12-09
CO4940407A1 (es) 2000-07-24
IE980284A1 (en) 2000-07-12
HUP9800882A2 (hu) 2000-03-28
FI980846A0 (fi) 1998-04-16
RO120043B1 (ro) 2005-08-30
PE75399A1 (es) 1999-08-17
PL326134A1 (en) 1998-12-07
SE9801336D0 (sv) 1998-04-17
HUP9800882A3 (en) 2000-07-28
ITMI980908A1 (it) 1999-10-28
NZ330192A (en) 1999-08-30
DE19823940A1 (de) 1998-12-03
CZ114398A3 (cs) 1998-12-16
JPH10330253A (ja) 1998-12-15
ES2161574A1 (es) 2001-12-01
LV12176A (lv) 1998-12-20
LU90245A1 (sr) 1998-11-30
PT102152A (pt) 1998-12-31
AU6904898A (en) 1998-12-03
LV12176B (en) 1999-03-20
CA2234826C (en) 2000-12-19
KR100549473B1 (ko) 2006-03-23
HU9800882D0 (en) 1998-05-28
UA48193C2 (uk) 2002-08-15
CN1285189A (zh) 2001-02-28
FR2763846A1 (fr) 1998-12-04
MY118139A (en) 2004-09-30
YU16598A (en) 1999-11-22
JP3210288B2 (ja) 2001-09-17
USRE39030E1 (en) 2006-03-21
SI9800128B (sl) 2000-04-30
SI9800128A (sl) 1999-02-28
AT408068B (de) 2001-08-27
ATA93198A (de) 2001-01-15
PL192293B1 (pl) 2006-09-29
SE9801336L (sv) 1998-11-30
NO982197D0 (no) 1998-05-14
DE19823940B4 (de) 2010-04-29
BR9801989A (pt) 2000-02-08
GB9807939D0 (en) 1998-06-10
US5985322A (en) 1999-11-16
NL1009259C2 (nl) 1998-12-01
LT4477B (lt) 1999-03-25
FR2763846B1 (fr) 2001-05-18
CA2234826A1 (en) 1998-11-29
FI119971B (fi) 2009-05-29
SE522914C2 (sv) 2004-03-16
KR19980086622A (ko) 1998-12-05
CH693018A5 (de) 2003-01-31
RS49827B (sr) 2008-08-07
LU90245B1 (fr) 2002-07-31
CN1161109C (zh) 2004-08-11
FI980846A (fi) 1998-11-30
ZA983173B (en) 1999-10-15
AU726690B2 (en) 2000-11-16
NO317743B1 (no) 2004-12-13
ID20343A (id) 1998-12-03
LT98058A (en) 1998-10-26
CZ290582B6 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
US5910319A (en) Fluoxetine enteric pellets and methods for their preparation and use
EP0693282B1 (en) Duloxetine enteric pellets
US5084287A (en) Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US20120003303A1 (en) Oral enteric antidepressant formulation
IE83510B1 (en) Fluoxetine enteric pellets
MXPA98003636A (es) Granulos entericos de fluoxetina

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees